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Summary
Before new drugs are approved for marketing and doctors are allowed to prescribe
them to patients, their eff icacy and safety are extensively studied. An important part is
formed by the cl inical tr ials test ing the new drug against placebo or other drugs.
Administration of the study dmg and its comparator should prevent identification by the
patient and the physician. Application of this so-cal led double-bl ind methodology reduces
bias in the tr ial  results as much as possible. Cl inical tr ials are conducted in dif ferent fypes
of populat ions. For phase II I  tr ials populat ions are defined to resemble the recipient
populat ion after marketing. Phase II I  cl inical tr ials are performed in selected patient
populat ions. The exclusion from cl inical tr ials of elderly and female patients, patients from
ethnic minorit ies and patients with co-morbidity and co-medication, is often.just i f ied by
the need for homogenous trial populations. As a result, by redr.rcing the co-variables, the
internal validity of trials is enhanced. At the same time, however, it reduces the applica-
bi l i ty of tr iai  results to medical practice, whe re large variat ion between patients exists. This
gap between cl inical research and medical practice has been widely recognised. I t  poses a
problem to doctors, pharmacists and patients, who want the r ight drug to be prescribed to,
del ivered at and used by the r ight patient at the r ight t ime and in the r ight dosage. Other
important actors in the pharmaceutical Í ie1d also experience this problem, in part icular
the government, health care insurers and pharmaceutical companies.
The gap between clinical research and medical practice forms an important issue in the
scienti f ic debate about evidence-based nedicine. The concept of evidence-based medicine
is that diagnostic and therapeutic methods, which are appi ied by physicians, need to based
on scienti f ic evidence. Therefbre, i t  is essential to use the results from systematic analyses
ofresearch data. Two core issues have been identified regarding systematic analyses. The
first one refers to the assessment ofthe scienti f ic qual i ty ofresearch data. The second issue
refers to the general izabi l i ty of data from selected tr ial  populat ions to popuiat ions in
medical practice the results from the systenatic analysis are appl ied to. A specif ic issue
regarding the use of new drugs in the context of evidence-based medicine is the i imited
availabi l i ty of publ ished research data.
The issue of the gap between cl inical research and medical practice, in part icular
regarding new drugs, is the central theme of this thesis. At present, few empir ical studies
have focussed on differences between populations in clinical trials and in daily practice
using new drugs. Studies in this f ieid focussed primari ly on demographic patient
characterist ics, i .e..  age. sex and ethnic origin. Also, most of the studies have been per-
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folned ir-r t l ' re Llnited States. Tl.re aim of present str.rdy is to contr ibute in two wavs to the
scit ' r t t i t ic r-eserrclt  regalding cl i Í ïêr 'cnces between pre-marketing cl inical rtscarch aud
n-rcdical plact ice. First ly, this studv was designcd to investigate the nàtl l re and size of
dcr-nographic and discase-related i f lerences between patients in premarketing research
aud nedical practicc. Cardiovasculal dmgs rvcrc. cl toscn fbr t l -re study, becanse thev 1re
rvidcly used, by both younger and oldel patients, oÍ whom the latter oÍten present wit l .r  co-
norbidity and co-medicatior.r.  Sccondly, this studv was designed to investigate the gap
betrvceu cl ir-r ical research and nredic:r l  practice f i-orr the pcrspective of n-redical
practi t ioners. Thercfore, t 'nlo apploacl les were used. ' fhe f irst approach was to study how
ac:idenic and professional opinior-r leaders asscss new drugs and whether they consider'
dif Ïêrer-rces between paticnts in tr ials and in medical practice r. t 'hen they prescribe new
drugs; in other $,ords, the relevancc of the issue. The second approach refels to the
question lvl'rich cl-ranges in drug lcgr-rlation are considered nc'cessary, according to the
opinion lcaders, iu clrdcr to opti lnisc Ihe cor-rnection beflveen rc.search and practice f i 'our
the perspective of evidence-based rncdicinc. In sunmary, the rcsearch objectives were as
fbl lows:
1 ' fo detelt t t ine the discrepancies lcgarding age and sex distr ibution. ethnic origir.r  o[
patients and patterns of co-morbidity and co-medication between phase II I  tr ial  popula-
t ions and patients ir .r  rnedical practice using cardiovascular drugs.
2 To investigate the considerations ust 'd by academic and professional opinion leaders in
thc assessment of r-rew cardiovascular drugs, whethel they are famil iar with under-repre-
sentation of subgroups of paticnts in pre-narketing tr ials, to.rssL.ss i ts cl inical relevance
and which changes in di 'ug regrt lat ion are cot 'rsidercd necessary to irnprove thc connec-
t ion between pre-marketir .rg cl inical tr ials and medical pr:rct ice.
To study the f i lst rcsearch qr,rest ion, phalmaco-epiden-riological metl ' rods nere used.
Thirty cardiovascular drugs were registered in the Nethcrlands in thc period frorn 1985 to
1995 fbr the indications mild to nodelate hypeltension. angina pectoris, hypcrcholes-
terolaemia or mvocardial infarct ion. Fif Ïeen of these \\ ,1.r 'c selectcd for t l -r is studl ' .  Included
nere f ive ACE inhibitors/angiotensin-l l  antagonists, thrcc calciunr channel blockers, two
beta-adrenergic blocking agents, one vasodilator, two HMG-CoA reductase inl-r ibi tols and
trvo thrombolyt ics. Thre'e drugs werc registcled fol both hypertcnsion and angina pl.croris,
bt ' inging the total number of registr-at ion f i les included in the study to 18. A regrstrat ion
fi le is con.rpi led by the pharuraceutical corlpanv applying for registrat ion ofthe nerv drug.
It  contains al l  the inÍbrmation rcgarding the quàli ty, eff icacy and safetv of the drug which
is used for assessmcnt by regulatory authorit ics to dccide on nrarketing approval.
In this study, chalacterist ics of the phase II I  tr ial  populat ions were coi lrpared with
those of paticnt populat ions in dai lv practiur..  As a refèrence populat ion, data f ion'r the
Registrat ion Network Groningen (RNG) were used. This database was st i l r ted in 1989 by
general practi t ioners and contains al l  data from their practices. For this study data were
r,rsed Í i-om 13 genet'al plact i t ior lers r.r ' i th a total patient populat ion of 2),199. Al l  patients
\4'ere selectcd who had leceived at last one prescript ion in 1994 of 1995 fol a drug f iom one




of the selected drugs. To define meaningful dif ferences, the'same classiÍ icat ion was ustd
as in a US study regarding the representation of tèmale patients in cl inical tr ials. ' IhtLs,
moderate discrepancies were defined as dif ferences of 10 to 20% in age and sex distr ibution
and disease prevalences between the tr ial  and RNG populat ions, large discrepancies were
differences more than 20?0.
Chapter 2 presents the results of the con-rparison of demographic characterist ics. The
age and sex distr ibution of al l  patients involved in 218 phase II I  tr ials were analysed and
compared to those frorn the RNG patient populat ions. The ethr.r ic origin of patients is not
recorded in the RNG database. Therefore, a comparison of this patient characterist ic was
not possible. Cl inical tr ial  data rc'garding the ethnic origin of patients, and the male/
fenrale rat ios of the populat ions, werc analysed by region oÍ ' tr ial  perfbrmance.
Patients older than 65 years accounted for more than 50% of the populat ion in dai ly
practice using drugs for hypertension, angina pectoris and myocardial infarct ion. Elderly,
as well  as female patients, were under-represented in the. cl inical tr ials of the drugs
registered for these indications. Trials performed in North An-rerica included relat ively
fewer fèmale patients comp:ired with European tr ials. In a l imited number of registrat ion
fi les tr ial  results were analysed by agc or sex. These analyses general ly involved onlv
descript ive stat ist ics.
Analysis by sex and age revealed over-representation of male patients younger than 45
years and female patients aged 45-65 years in the f i les of drr-rgs registered for hypertension.
Younger male patients were also over-represented in the f i les of drugs registered fbr
hypercholesterolaemia. Discrepancies regarding elderly were found for male and fenale
patients, but above 75 vears they involved in part icular female patients.
European tr ials included primari ly Caucasian patients. North American tr ials of
antihypertensive drugs included on average one-third non-Caucasian patients, whereas the
tr ials with cholestefol lowering drugs, r 'cpresenting a new drug c1ass, included more than
90!1n Caucasians.
From the results i t  is concluded that cl inical ly relevant subgroups of cardiovascular
patients were under-represented in pre-narketing phase II I  tr ials of widely r-rsed rugs. Age,
sex and the ethnic ol igin of patients are wcl l-knolvn rnodif iers of the etïcacy and safery of
cardiovascular drugs. Therefore, the r lse of drugs by patients with other characterist ics
than those in the tr ials may result in a dif ferent eÍf icacy and/or safèry. Data from phase II I
tr ials should be conclusively analysed in lelat ion to demographic variables in order to
provide a better understanding ofsuch cl i f ferences.
Chapter 3 focuses on the patterns of co-morbidity and co-medication of patients
included in the phase II I  pre-marketing tr ials. Co-rrorbidiry refers to one or more other
diseases co-exist ing to the one the drug is indicated for. In the case of co-medication other
drugs are used concornitantly to the studv drug. Both are relevant factors which may alter
the efï icacv and/or safety ofdrugs. In this studv, the avai labi l i ty ofdata in the registrat ior-r
Í l les was inrestigated, and the patterns of co-norbidity and co-medication. Furthermore,
dif ferences in co-morbidity and co-medication of patients were studied according to the
region of tr ial  pelfolmance, and the irnpact of patient selecÍ ion cri teria regarding
coc,xist ing diseases on the actual inclusion of such patients.
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Thirteen ont of 18 registration files contained data regarding co-morbidity and co-
rnedication of patients in phase III trials. The products involved were registered for
hypertension, angina pectoris or hypercholesterolaemia. Large variat ion was found
between the registrat ion f i les in the report ing of data and in patterns of co-morbidity. In
contrast to the general notion of exclusion from tr ials of patients with co-morbidity and
co-medication, the results of this study show that pre-marketing trials were performed in
populat ions which included such patients. Concomitant cardiovascular, endocrine and
metabolic diseases were most frequently documented, in part icular in the f i les of drugs
registered for angina pectoris and hypercholesterolaemia. As expected. the patterns ofco-
medication corresponded to those of co-morbidity. Patients included in North American
trials on average had more coexisting diseases and co-medication compared with European
tr ials.
The patient select ion cri teria related to concomitant morbidity and medication varied
in descript ion and content. Differences in definit ions of concomitant diabetes, heart
failure or hypertension (tl.re latter only regarding drugs registered fol angina pectoris)
resulted in dif ferent levels of inclusion. Also, tr ials were found to include patients when
this was not allowed and vice versa. Therefore, the actual trial populations may differ from
the intended populat ions, as defined by the selection cri teria, with respect to co-variables
which inf luence the disease prognosis.
The results ofthe study are discussed in relat ion to the question ofwhether the general-
izabi l i ty ofpre-marketing tr ials can be enhanced by further ut i l isat ion ofdata from these
heterogeneous populations. The issue to study is variability between saÍèty and efficacy in
patient groups with dif ferent patterns of co-morbidity and co-medication. In order to al low
regulatory authorit ies to consider patterns of co-morbidity and co-medication during the
evaluation of registrat ion f i les, development of guidel ines for uniform report ing of data in
pre-marketing trials is recommended.
In chapter4, the prevalences of concomitant cardiovascular, endocrine and metabolic
diseases were compared between populat ions in the pre-marketing tr ials and the RNG
database. Data from 13 registrat ion f i les were avai lable íor analysis. Data were also
col lected about the number of tr ials focussing specif ical ly on patients with co-morbidity.
Coexisting cardiovascular, endocrine and metabolic diseases were generally less
prevalent in the pre-marketing popuiat ions as compared to patients in the RNG
populat ion. Ischaemic heart disease and l ipid disorders formed an exception to this
pattern, because these were more prevalent coexist ing with angina pectoris and hyper-
cholesterolaemi a.
Discrepancies were found for all indications, but for different concomitant diseases.
Prevalences of concomitant cardiovascuiar diseases of patients using antihypertensives in
the RNG populat ion were al l  less than 10.,(, .  Therefore, dif ferences did not reach the
thleshold level at which discrepancies were classif ied. In contrast, discrepancies were
Íbund for the indications angina pectoris and hypercholesterolaemia. Patients with co-
existing hypertensive disease and heart failure were under-represented in the trial
popuiat ions, whereas patients with a history of myocardial infarct ion were over-
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diabetes, which was more prevalent in thc RNG populat ions. Tl 'rese discrepancie,s were
present for drugs registered for hypertension and angina pectoris. Only in Í-our rcgistrat ion
fi les of antihypertensive products specif ic phase II I  tr ials tbcussing on patients with
concomi tan t  mo lb id i ry  werc  pcr lo rmed.
Thcse results suggest that the lack ofreport ing and under-ut i l isat ion ofdata regarding
patients with co-nrorbidity appear to be a l imitat ion in the exte mal val idity of pre-market-
ing phase II I  tr ials. With respect to a better understanding of safety issues of new drugs,
our stucly re-emphasises the l ini ted value of ple-marketing tr ials, because of the snal l
numbcrs of patients with complex diseases snch as heart f :r i lure. However, information
about safety aspects in these pàtients are l ikel l '  to be highly relevant in dai ly practice.
Chapter 5 presents the results of an analvsis of the comparative phase II I  tr ials in the
registrat ion f i les, the nature of the comparator drugs and their dosing schemes. ' I 'his
analysis was conducted because a nur-nbel of persons, who were interviewed for the second
research qr. lest ion. had mentioned a lack oÍ 'data frorn snch studies lvhen ne'nv drugs are
marketed.
Sixteen out of 18 registrat ion f i les were included in the analysis. In haif  of the 146
double-blind trials the ner'v drugs was compared lvitl.r another, active drug. Twelve
registrat ion f i les contained both placebo and active nedication control led double-bl ind
tr ials, one Í i le only placebo, and three f i les only act ive control led tr ials. The majori ty of
regist lat ion f i les included comparative tr ials with Í irst cl-roice drugs ivi thin the same and
within other therapeutic classes. In six tr ials dif ferent dosing schet.nes were used.
Furthermore, maxinum doses were more often included Íbr the test drug, than for the
comparator drug.
The use of only act ivL. control led dolrble-bl ind tr ials and the diÍTerences found in dosing
schedules for study and comparator drugs are in principle sources of bias in demonstraring
eÍïicacy of drugs. In general, this is likely to over-estinate the study drug's efficacy.
Tl-reretbre, basic detai ls of tr ial  design, sLlch as the choice of reference drug and dosing
schemes, need to be stated when communicating data from pre-narketing tr ials to n]edical
practice. The Europear-r Medicines Evaluation Agency, EMEA, airns to improve transparency
ofthe regulatory process by publishing European Public Assessrnent Reports (EPARs) on the
internet. EPARs contain a sunmary of the cl inical tr ials nscd as a basis for approval and
reflect the considerations for granting approval. To irnprove the interpretation of these
data, i t  is recommended to develop uniform report ing ou basic detai ls of tr ial  design.
To study the second research questiol l ,  regarding the gap bctween cl inical t 'esearch and
medical practice Í iom the perspective of nredical practice, qual i tat ive resealch rnethods
were used. This palt  of the study involved two approaches, i .e.,  the assessnent of 'new drugs
in practice and the relevance ofdata from research invarious subgroups ofpatients, and
the investigation of changes in drug regulat ion whichwere considered necessaly in order
to optimise the connection between research and practice. Sernistructured interviews
were  conducted  w i th  47  spec ia l i s ts  in  in te rna l  med ic inc ,  card io log is ts .  genera l
practi t ioners, hospital and community pharnacists throughout the Netherlands. The
interVieWeeS 1yg1E. jnyglrrorl in the rrrÍi- ^ Í nnsl-pi11ftg6ing evaiLlatign Of CardiOVaSCUlar
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dlugs, fbr L.xanple thlough cl inical researcl-r or assessnent oÍ new drugs for thelapentic
guidel ines. In the intervicws, the research issues were addlessed in ger-reral and in the
spccific case of a newlv marketcd cardiovascular drug. Two semiir-rnovativc drlrgs lvere
chosen Íbr the case strrdy. LosrtLtan rvas the f irst replesentative of a nL'\ \ '  class of
antihypertensives and atorvastat in was a cholesterol- lowering dlug whicl i  was clained to
have a stronger effcct than the ot l ' rer products in i ts class.
In chapter 6 thc considerations wclc analvscd whicl ' r  the plofessional and academic
leaders ust 'd to assess the posit ion of ncw cardiovascular drugs in the theraper-rt ic regimen
in lelat ionsl-r ip to thcir profèssional characterist ics, and level ofprescribing.
In each interview, t l ' re responrlents wcre asked about eithcr losartan or atorvastat in.
Cor-rsiderations to :rssess t ire thelapeutic posit ion ol '  the drulJs leÍèrred to their relat ive
advantage, cornpatibi l i ry with the lcspondents' opir.r ions and cornplexity of the drug.
Characterist ics of the interviewcr.s, which were applicable or not, reÍèrred to: their
protèssion. acadcmic afï i l iat ion, involvement in t l-re development of treatlnent guidel ines,
specif ic expL-r ' t ise ir-r hypertension or l ' rypelcholesterolacnia. rnentioning comnercial
sources of information to learn about losartan or atorv:rstat in, and selÊr'eported
quali f icat ion :rs (n-roderatc. ly) earl-v adopter of new dmgs. The selÊreported levels of
prc'scribing of losartan and aton/astat in rvr 're classit ïcd as Í i 'equcnt, occasional, or non-
prescribing. Tl-rr-ough the numbers of responclents n-icntioning advantageous, comparable
a n d / o r  d i s a d v a n t r g t , o r r s  c h a l a <  t e r i s t i c s  o I  l o s l l t a r r  o r  r l o r v a s l l t i n .  p a l t e r n :  r r ' e l e
constructed to analyse thc evalnatior-r of the dlugs in lelat ionship to professiolral
characterist ic 's and the level of plc.scribir-rg.
The results sl ' rowcd that thc majori fy of considerations refcrred to the dcgree of relat ive
advantage, but dif ferent subjects rvele emphasisecl for both drugs. The efÏ icacv of
atorvastat in was predorninanth, '  consideled relat ively advantageous t)1'  cornparable to
colnpcting drugs, whereas the eÍÏ icacy of losartan was cor-rsidered relat ively disadvanta-
geous to such drugs. Losartan onlv scored rnore posit ivc. on side-cffects. Thcrefo|e, nrrny
cor-rsicierat ions used to i issess the value oÍ bolh drugs in the therapeutic regir-nen fbcussed
on the claims that were made during rrarketing, i .e.,  Íèwer side-efïccts when using losartan
and higher efï icacy with atorvastat in. However, some respolldents posit ively acknowledged
thest. c1:r inrs, lvheLeas others were not convinced by thc claims ol disagreed.
The patterns of evaluation oÍ the' drr.rgs gcneral ly showed an intermediatc or negative
assessment. A rrore posit ive cvaluation was found in relat ion to the respondc'nts'
profèssion, the mentioning of comurercial sources of infbrmation and scl l :cpral i Í lcat ion as
(r-noderatelv) early;rdopter of new drugs. In contr i lct,  specif lc expert isr.  ar-rd acadcnic
aff l l iat ion made no diÍ lèrencc in t l ' re evaluation of the drugs. A nurnber of characterist ics
rcsulted in a rrore posit ive evalual ior-r in thc case of losartan, but not of atoNastatin. This
rcfel led to the mentioning of comurercial st lurces of infbrmation and self-qual i f icat ion as
(r-r-roderately) early adopter of nclv drugs. A possiblc e.rplanation fol thesc Í)ndings is that
the evaluation of a dlug with less perceived advantages is mole likely to be inflr-rer-rced by
conrmcrcial soulces of infbrmation. Only in thc case oÍ losartan i t  n'as Íbr.rnd that f i 'eclr.rent
prescribing physiciarrs had a nore posit ive evaluation of the drug, cor.npared with the
o t t n s i o n ; r l  r r r r d  n o t t - p r e s c r i b i r t g  p h y s i c i l r n s .
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Fror-n rhis study i t  was concluded t l iat proÍèssional and academic opinion leaclers
cri t ical ly cvaltratecl the cl:r in-rs rvhen asscssing the posit ion ofnerv drugs in thc thelapeutic
reginen, but did not show consensus in thei l  considcrations. Accepted principles fbr
prescribing were consideled, but rcsulted in varied tendcncics Ítr l  prescl ibir.rg.
In chapter 7 the cl inical relcvance oÍ the gap between pre-narketing tr ials and r-r ' redical
practice was studlecl.  Ihe opinion Ieaders were asked about t l -rcir f i lmil iar i ty wlt l ' r  under.
representation ()f  r- 'klerl l ' ,  Í-cmale paticnts and patients wil l -r  co-norbidity in pre'marketing
tr lals of c. irdiovascular drugs, the relcvance attr ibuted to under.reprr.sentat ion, the types
of ar-gunrents uscd and thr. cortsc'qucnces oÍ perceir,'ed r-epresentation fbr presclibing. Tr.l,o
approaches were used, addressir-rg t l- tc issue in general and fbr the speciÍ ic cases of losat ' tan
and atorvastat in. To addre ss the issr,re in genelal,  thc responclcnts receivcd writ ten
inforn-rat ion containing the ln:r in lcsults of t l ie comparison between pre- and post-
n-rarketing populat ions using cardiovascular dmgs.
Tl 're majol i tv of intrrviewees rcported to be Iamil ial  with thr. ' fact that elderlv, Íèn.rale
paticnts and patients with co-nrolbidity ale gener:r l lv undetleprcserltcd in pre-uralkct ing
tr ials oÍ 'cardior.nscular dlugs. T1-rey wcre less falr-r i l iar rvi th the dr.tai ls of representation ir-r
the cases of losartan arnd aton,astat in. Undcr-replesent]t i r)r1 \vas not considerecl a re'asol l
not to plcscribe these dmgs to such patients. fhe cl inical relevance' of under-reprcsen-
tat ion, specif icai ly lcgarding cldel ly and patients with co-morbidiry, was alï irmed by the
ma.iori t-v of respondents. but lcÍhted by others. Alguments uscri  to af l lnn ol lefute the
cl inical relcvance of under.representatiou reí 'crred to tr ial  mc'thodology, appl icabi l i tv of
t l ial  resr,r l ts and patient treatnent. Furthelr-nole, precondit ions werc attached to the
cl inical lelcvance rvl-r icl ' r  lefèr-rcd to the ain-rs of tr ials, thc prescnce of suÍï icier-rt  patients to
perform subgroup analyscs, cl i f Íêrcnces betwcen therapeutic drug classes and thr t ining
oftr ials prior to or after drug approval.
T h c  l r r g u n r e r r l s  s u b s t u n t i n t i n g  t l t e  t l i r i i c u l  | t ' l e v : r n r ' e  s u g g e s l  t w o : t | a t c $ i t ' s  t o  o p t i t n i s e
the connection bct." l 'ee'n pre-u'rarketing cl inical researcl 'r  and medical practice. F' irst ly,
cl ir-r ical tr ials test ing nen, drugs should fbcus urore on paticnt populat ions th:rt  reprcsent
relcvant tal-gL't  grol lps in dai ly practice. \Mren such reseaLch is not considercd fèasible'
pf ior to drug registrat ion, i t  should bc conducted aí ' tcl  rnalketing. Secondly, inÍbrnation
about ncw druss should al lon'the dctermination of val iat ions in the relat ive treatn)ent
ef1èct between sr-rb-populat ions. 'Lher-efore. i t  is rclevant to develop fbrmats which plovide
sucl.r detai ied infornration f i 'our plc'marketing tr i :r ls. These developments shotr ld faci i i tate
assessnlent ofnew drugs in the context of evidelrcebascd mcdicine.
In chapter 8 core issnes weLt'  studied r 'r 'hich conrrÍbute to the gap betwcen pre-
nalketing cl inical researcl 'r  and clai lv practice, proposed changes whicir may be necessary
to bridge t ir is gap, the actors involved and potential barr iers to changc.
The interviewecs pl:rced tht issue of diÍ Icrelrccs between populat ions in pre-markcting
tr ials and in medical practice in thc blo:rder contcxt of dlug development, cl inical
resealcl-r,  reir-nbursr- 'nrent pol icies and prcscl ibing. They a;rpointcd issues in clrr,rg
legulat ion which general ly referred to the standalds usecl and the organisation ol the
l t g u l l t o n  s v s t e n ) .  l r r  p l l t i c t r l . r r ' .  t l r t , s t . i s s u e s  l r l ê r ' r ' t ' t l  o  I l t a n  i n s u l l ' i r ' i c n 1  l o c l l \  o í  p l c -
narkcting tr ials or-r patient groups and rcsearcl-r issues rc' levant to nedical practicc; (2) t l ie
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discrepancy between rcquirenents for dmg approval. general iy i l rvolving demonstrat ion
of efÍ icacy ol1 surrogate cndpoints, and t1're prescribing of drug in rnedical practice which
is increasingly'based on evidence ofeffect iveness; (3) absence ofthe r isk/beneÍl t  assessment
r.r, i ren drugs are pi 'escribed off- label: (4) the lack of possibi l i t ies to veri Íy the quali ty oÍ ' the
regulatory process because of i ts confidential nature; (5) the l imited possibi l i t ies of
regulatory authorit ies for steering research and development of new drugs, in part icuiar
aftcr marketing; (6) the lack of infblrnation anong practi t ioners'"vhen they e'naluate new
drugs for appl icat ion in dai ly practice.
According to the professional and academic opir.r ion leaders ir .r  the cardiovascular f ield,
drug regr-r lat ion should fbcus more on the needs in nedicai practice. With respect to
regulatoly standards two major subjects wele mentionecl by the respondents. t .e.,
variabi l i ty in drug response and demonstrat ion of cl inical ef ' fect iveness. Both issues are
scienti f ical ly important and need to be dealt with in terns of drug regr.r lat ion in the pre-
o I  pos t -n rark ( j t  i r rg  p l t rse .
A wide variety oÍ changes and actors involved were proposr.d by the respondents in
order to inrplove tl're connection betwecn pre-marketing research and nedical practice.
Regulatory aurhorit ies rvcre identi f ied as prin-rary actors to init iate changes. Furtherrnore,
thc '  pharnaceut ica l  indus t ry ,  c l in ica l  inves t iga tors ,  e th ics  commi t tees .  p rac t ice
researchers ,  governmr 'n ta l  hea l th  care  au tho l i t ies ,  p rac t i t ioners  and pro fèss iona l
organisations need to be involvcd. Dependent on the nature ofchanges in drug regulat ion
which mav be ain'red for, a number of potential barr iers shor.r ld be considered.
Based or.r the analysis of the results two strategies tor change could be identi f ied. Fi lst ly,
strategics which can be applied within thc present system of drug regulat ion. These
typical ly involve pol icies ."vhich ain.r to increasc the fbcus of cl inical resealch on subgroups
of patie'nts relevant to practict ' .  The prescnt development that regulatory author-i t ies
consult various organisations about certain pol icies also f i ts into this strategy. The second
strategy introduces new basic principles to the process ofdrug regulat ion. Trvo fundamen-
tal principlcs rvere idenriÍ ied. In the f irst place, the introduction of an intelact ive posr-
nalketing drug development process. A part icularly i t ' t ' rportant part of drug innovation
takes place in the contcxt of nedical practice. However, apart from regulat ing post-
marketing pharmacovigi lance, regulatoly aLrthori t ics loose their act ive power to inf luence
research and developrncnt after registrat ion. I t  was considered necessary to reach a bettcr
balance ben'veen the interests oÍ 'phannaceutical companics and those of the public in
post-marketing research. The second principle that was introduced, refers to the develop-
nrent of a regulatolv svstem in which more part ies parr icipate than just the regulatoly
;rr.r thori t ies and pharmaceutical companies, as is the case in the present system. Also. the
cl lrrent coníider-rt ial i ty of the present system was clearly recognised as a pfoblem. Provid-
ing inftrrmation on the scienti f ic assessnent of drug approval by publ ishing EPARs is in
i tselÍ  a posit ive developnent, but from the perspective of medical practice i t  can onlv be
valued in ten.rrs of a f irst step towirrds openness and public debate.
The need for reorientation fi'oln a drug centred regulatory system towards a practice
oriented process is also recogr-r ised.,r ' i thir-r the regulatoly al l thori t ies. From this study i t  is
recommended that regulatory antl-rori t ies develop tht ir  inf lr-rence on the post-marketing
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drug research process, together with other part ies involved, in order to bridge the gap
between pre-marketing rescarcl-t  and medical practice.
Final1y, chapter 9 integrates the results of these studies. Based on the data frorn the
phannaco-epidemiological str-rdie.s, i t  is concluded that phase II I  pre-rnarketing tr ials of
cardiovascular drugs from widely used therapeutic classes were performed in highly
selected patient populat ions. This resuits in cl inical relevant discrepancies between
populat ions in rescarch and medical practice. From this study i t  is concluded that l i t t le
research was perforrned to identiÍy possible differences in efficacy and/or safefy between
subgroups of patients in the phase II I  pre-marketing tr ials of these drugs. Such data,
however, are l ikely to be of great i l rportance to practi t ionefs, because they deal with
patients who present with a wide variety of characterist ics. To study variabi l i ty in efï icacy
and safety ofnew drugs, i t  should become a core issue ofpre-nrarketing research,
The gap between pre-marketing cl inical research and rnedical practice was recognised
in palr icuiar as a general problen.r and as such i t  was considered cl inical ly relevant. In the
case of a specif ic new drug, less than half of the interuiewees stated to be famil iar with
detai ls of representation of subgroups of patients in pre-marketing tr ials. Since the
interviewees operated closely to the process of drug regulat ion, these f indings can be
indicative for the l imited avai labi l i ty to r.r-re.dical practice of detai led infon'nation about
new drugs short ly after rrarketing. To faci l i tate evidence-based rnedicine i t  is lrnpoltant
that al l  infornlat ion from cl inical tr ials is a' , ,ai lable to medical practice.
A number of changes legalding drug regr.r lat ion was suggested to improve the
conncction between pre-narketing cl inical research and medical research. Changes
referred to the standards which are appl ied in drug regulat ion and the organisation ofthe
process. Issnes which are relevant to medical pfactice, in part icr,r lar variabi l i ty in drug
responses and demonstrat ion of cl inical eÍfect iveness, should become core issues in drug
regulat ion. Strategies for change can be applied within the present system of drug
legulat ion, or require the introduction of new principles. In part icular, regulatory
authorities shotild develop influence on the post-rnarketing drug research process and
create openness about rcquirements fbr ' ,  and the process of drug approval. Reguiatory
authorit ies should be t1-re prinary actors to init iate changes, bnt other part ies need to be
invol','ed.
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